Navigation Links
Arcturus Therapeutics Announces Collaboration with Takeda Pharmaceuticals to Develop RNA-based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Date:12/6/2016

SAN DIEGO, Dec. 6, 2016 /PRNewswire/ -- Arcturus Therapeutics, Inc. ("Arcturus" or the "Company"), a leading RNA medicines company, announced today that it entered into collaboration with Takeda Pharmaceutical Company Limited, to develop RNA-based therapeutics for the treatment of NASH and other gastrointestinal (GI) related disorders, utilizing Arcturus' wholly-owned therapeutic delivery platform LUNAR™ and UNA Oligomer chemistry. The financial terms were not disclosed.

"Given Takeda's long-standing commitment to and expertise in GI disorders, we are confident we have found an ideal partner to accelerate and maximize the potential of our LUNAR and UNA technology platforms toward the development of novel RNA therapeutics for the treatment of NASH," said Dr. Pad Chivukula, CSO & COO of Arcturus Therapeutics, Inc. "This agreement underscores Arcturus' ability to rapidly discover, design and optimize RNA medicines in areas of unmet need." 

About Arcturus Therapeutics, Inc.   

Founded in 2013 and based in San Diego, Arcturus Therapeutics, Inc. is an RNA medicines company with enabling technologies — UNA Oligomer chemistry and LUNAR™ nanoparticle delivery. Arcturus' versatile RNA therapeutics platform can be applied toward all types of RNA medicines including small interfering RNA, messenger RNA, antisense RNA, microRNA and gene editing therapeutics. The company owns LUNAR™ nanoparticle delivery and unlocked nucleomonomer agent (UNA) technology including UNA Oligomers™, which are covered by its patent portfolio (77 patents and patent applications, issued in the U.S., Europe, Japan and other countries). Arcturus' proprietary UNA technology can be used to target any gene in the human genome, as well as viral genes, and other species for therapeutic purposes. The Company's commitment to the development of novel RNA therapeutics has led to collaborations and license agreements with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and Ultragenyx Pharmaceutical, Inc. For more information, visit www.ArcturusRx.com.

Logo - http://photos.prnewswire.com/prnh/20130531/MM24393LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/arcturus-therapeutics-announces-collaboration-with-takeda-pharmaceuticals-to-develop-rna-based-therapeutics-for-the-treatment-of-nonalcoholic-steatohepatitis-nash-300373830.html


'/>"/>
SOURCE Arcturus Therapeutics
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Arcturus Therapeutics Receives Intent to Grant Notice from the European Patent Office for their Unlocked Nucleomonomer Agent (UNA) Technology
2. Arcturus Therapeutics Announces the Appointment of Drew Weissman M.D., Ph.D. to the Scientific Advisory Board
3. Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines for Defined Indications
4. Arcturus Therapeutics to Present at the Genetic Rx Boston Biotech Conference
5. Arcturus Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
6. Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program
7. Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech
8. Viking Therapeutics Receives Orphan Drug Designation for VK0214 from the U.S. Food and Drug Administration for the Treatment of X-Linked Adrenoleukodystrophy
9. Mission Therapeutics Appoints Colin Goddard as Chairman
10. Research Reports Initiation on Healthcare Stocks -- NuVasive, Smith & Nephew, Nxstage Medical, and Cesca Therapeutics
11. Research Reports Coverage on Biotech Stocks -- Celldex Therapeutics, Amicus Therapeutics, Navidea Biopharma, and Concordia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2019)... (PRWEB) , ... October 08, 2019 , ... ... year at Western Pennsylvania & Ohio Valley Oral & Maxillofacial Surgery. This cutting-edge ... from All-on-4® full arch dental implants to predictable jaw surgery with ...
(Date:10/8/2019)... ... October 08, 2019 , ... Fresno resident Regina Tanner has been selected by ... donor honoree. Regina will walk alongside the float, Light in the Darkness, during the ... and attorney, became a living organ donor in the fall of 2016 when her ...
(Date:10/8/2019)... ... ... A free, interactive event highlighting innovations and ideas helping people with Parkinson’s ... leaders, innovators and health experts, will display innovations that could help people with Parkinson’s ... CT on October 19 at the Coppertank Event Center in Austin, the event is ...
Breaking Medicine Technology:
(Date:10/15/2019)... ... 2019 , ... Nashville Fertility Center (NFC) is proud to announce that ... practice. In addition to treating general infertility, Dr. Van Heertum offers expertise in fertility ... forward to Dr. Van Heertum joining the practice and believes she is the perfect ...
(Date:10/11/2019)... ... October 11, 2019 , ... A Topping Out event was hosted ... by general contractors Adolfson & Peterson Construction. The event celebrated reaching the final height ... Road in Dallas. The first of its kind in Texas, STA’s facility will be ...
(Date:10/10/2019)... ... 10, 2019 , ... Caring.com, a leading senior care referral service with Family ... for Seniors to Live. All 50 states and 302 cities in the U.S. were ... development. , According to the U.S. Census Bureau , almost 20 million ...
(Date:10/8/2019)... ... 2019 , ... What unique insights can three former Surgeons General of the ... the nation? That question will be answered at ICAA 2019: Shaping the Future of ... event will take place October 10-12, 2019, at the Gaylord Palms Resort and Convention ...
(Date:10/8/2019)... ... October 08, 2019 , ... Dr. Amir HagShenas of Silicon Valley Smile Solutions ... relief from this common and treatable condition. Dr. HagShenas’ goal is to treat ... with uncomfortable symptoms, including tender and bleeding gums, and to prevent gum disease from ...
Breaking Medicine News(10 mins):